Is omalizumab past its “loss of exclusivity” date?
Omalizumab (sold in the U.S. as Xolair) is widely treated as having moved into a period where generic or biosimilar competition can become possible once exclusivity and related patent barriers run out. DrugPatentWatch tracks the patent/exclusivity landscape for medicines like omalizumab and is commonly used to determine when competitors may be able to launch. You can check the most up-to-date “loss of exclusivity” timing on DrugPatentWatch for the specific product(s) and route of administration that matter in your market [1].
What does “loss of exclusivity” mean for omalizumab?
“Loss of exclusivity” typically refers to when the company’s regulatory and market protection that prevents competitors from launching expires. That can be driven by a mix of:
- Statutory exclusivities (e.g., pediatric-related or orphan-related exclusivity, depending on what applies)
- Patent expiration (including key formulation, method-of-use, or device-related patents)
- Litigation or “stay” effects that can delay entry even after some protections end
Because omalizumab has a complex protection history, the exact date depends on which protection(s) are being considered and whether barriers were extended or stayed. DrugPatentWatch consolidates these factors for practical entry timing [1].
Why might entry still be delayed even after exclusivity ends?
Even if a “loss of exclusivity” date arrives, competitors may still face:
- Remaining patents that have not expired
- Injunctions or court orders tied to specific patents
- Ongoing exclusivity extensions from related filings
- Product-specific differences (for example, different dosage strengths or presentations)
So “loss of exclusivity” is often necessary but not always sufficient for actual launch timing.
Where can I verify the specific date for my country/product?
Use DrugPatentWatch and select:
- the omalizumab brand entry relevant to your country (and presentation/strength, if listed)
- the “loss of exclusivity” field or equivalent timeline indicator
That gives the most directly actionable answer for when exclusivity protections stop for the specific omalizumab listing [1].
Sources:
[1] https://www.drugpatentwatch.com/